Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma

British Journal of Cancer

Volumn 105, Issue 9, 2011, Pages 1322-1330

  Nagata, M ^a   Nakayama, H ^a   Tanaka, T ^a   Yoshida, R ^a   Yoshitake, Y ^a   Fukuma, D ^a   Kawahara, K ^a   Nakagawa, Y ^a   Ota, K ^a   Hiraki, A ^a   Shinohara, M ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; cellular inhibitor of apoptosis protein 2; oral squamous cell carcinoma; prognosis; resistance

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; SMALL INTERFERING RNA; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CHEEK MUCOSA; CHEMOSENSITIVITY; DNA MICROARRAY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MANDIBLE; MAXILLA; MOUTH; MOUTH CARCINOMA; MULTIMODALITY CANCER THERAPY; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TONGUE; TREATMENT DURATION; TREATMENT RESPONSE;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHEMORADIOTHERAPY; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MOUTH NEOPLASMS; PROGNOSIS; UP-REGULATION;

EID: 80054980154     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.387     Document Type: Article

References (42)

1. Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M, Lavertu P, Lorenz RR, Carroll MA (2006) Multiagent concurrent chemo-radiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 24: 1064-1071 (Pubitemid 46638803)
2. Aschele C, Sobrero A, Faderan MA, Bertino JR (1992) Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52: 1855-1864
3. Bell RB, Kademani D, Homer L, Dierks EJ, Potter BE (2007) Tongue cancer: Is there a difference in survival compared with other subsites in the oral cavity? J Oral Maxillofac Surg 65: 229-236 (Pubitemid 46127604)
4. Chen M, Wang J (2002) Initiator caspases in apoptosis signaling pathways. Apoptosis 7: 313-319 (Pubitemid 34832255)
5. Colevas AD (2006) Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2644-2652 (Pubitemid 46628471)
6. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC (1998) IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17: 2215-2223 (Pubitemid 28171907)
7. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM (2007) Survivin: a promising tumor biomarker. Cancer Lett 249: 49-60 (Pubitemid 46442669)
8. Ferreira CG, van der Valk P, Span SW, Ludwig I, Smit EF, Kruyt FA, Pinedo HM, van Tinteren H, Giaccone G (2001) Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res 7: 2468-2474 (Pubitemid 32751651)
9. Fulda S (2007) Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Rev Anticancer Ther 7: 1255-1264 (Pubitemid 47521021)
10. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA (2005) Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern cooperative oncology group. J Clin Oncol 23: 3562-3567
11. Herrmann R (1996) 5-Fluorouracil in colorectal cancer, a never ending story. Ann Oncol 7: 551-552 (Pubitemid 26285631)
12. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC (2003) Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 9: 2826-2836 (Pubitemid 36842129)
13. Hunter AM, LaCasse EC, Korneluk RG (2007) The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12: 1543-1568 (Pubitemid 47106887)
14. Ikeguchi M, Kaibara N (2002) survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer 87: 883-887 (Pubitemid 35252964)
15. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo BC, Kim HK, Park JG (2004) Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10: 272-284 (Pubitemid 38114190)
16. Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M, Okabe M, Ando T, Murata Y, Sasaki H, Takami K, Yamamura A, Shibata C, Sasaki I (2009) Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci 100: 903-913
17. Karin M, Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227
18. Kawano K, Goto H, Kanda T, Yanagisawa S (2003) Predictive value of immunohistochemical thymidylate synthase expression for histological response to tegafur/uracil (UFT) in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 32: 633-637 (Pubitemid 37461506)
19. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, Gao GJ, Reed JC (2003) Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 9: 4914-4925 (Pubitemid 37323298)
20. Lee SK, Kim SB, Kim JS, Moon CH, Han MS, Lee BJ, Chung DK, Min YJ, Park JH, Choi DH, Cho HR, Park SK, Park JW (2005) Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines. Int J Cancer 117: 32-40 (Pubitemid 41262757)
21. Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338 (Pubitemid 37328853)
22. Lopes RB, Gangeswaran R, McNeish IA, Wang Y, Lemoine NR (2007) Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer 120: 2344-2352 (Pubitemid 46642120)
23. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, Arora V, Mak TW, Lacasse EC, Waring J, Korneluk RG (2008) Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 105: 11778-11783
24. McCarty Jr KS, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT, Seigier HF, McCarty Sr KS (1986) Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46: 4244s-4248s (Pubitemid 16041242)
25. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L, Danenberg PV (1998) High basal level gene expression of thymidine phosphorylase (platelet-derived endothe-lial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4: 2371-2376 (Pubitemid 28477901)
26. Miura K, Karasawa H, Sasaki I (2009) cIAP2 as a therapeutic target in colorectal cancer and other malignancies. Expert Opin Ther Targets 13: 1333-1345
27. Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, Sato N, Shiraishi T, Nakamura T, Mikami K, Okihara K, Takaha N, Ukimura O, Kawauchi A, Nonomura N, Bonavida B, Miki T (2007) Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol 30: 919-925
28. Nachmias B, Ashhab Y, Ben-Yehuda D (2004) The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 14: 231-243 (Pubitemid 38824584)
29. Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, Takemura T, Suzuki K, Kitagawa M (2006) IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 81: 824-831 (Pubitemid 44682183)
30. Petersen SL, Peyton M, Minna JD, Wang X (2010) Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci USA 107: 11936-11941
31. Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355: 949-955 (Pubitemid 30148259)
32. Sasaki H, Sheng Y, Kotsuji F, Tsang BK (2000) Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 60: 5659-5666
33. Schimmer AD (2004) Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64: 7183-7190 (Pubitemid 39372048)
34. Shimosato Y, Oboshi S, Baba K (1971) Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jap J Clin Oncol 1: 19-35
35. Shingaki S, Takada M, Sasai K, Bibi R, Kobayashi T, Nomura T, Saito C (2003) Impact of lymph node metastasis on the pattern of failure and survival in oral carcinomas. Am J Surg 185: 278-284 (Pubitemid 36298898)
36. Tanimoto T, Tsuda H, Imazeki N, Ohno Y, Imoto I, Inazawa J, Matsubara O (2005) Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomas. Cancer Lett 224: 141-151 (Pubitemid 40720375)
37. Tsukuda M, Ishitoya J, Matsuda H, Horiuchi C, Taguchi T, Takahashi M, Nishimura G, Kawakami M, Watanabe M, Niho T, Kawano T, Ikeda Y, Sakuma Y, Shiono O, Komatsu M (2010) Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 66: 729-736
38. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, Fairbrother WJ, Vucic D (2008) c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 283: 24295-24299
39. Vucic D, Fairbrother WJ (2007) The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13: 5995-6000 (Pubitemid 350075054)
40. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E (2004) Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells. Cancer Res 64: 8167-8176 (Pubitemid 39491752)
41. Wu HH, Wu JY, Cheng YW, Chen CY, Lee MC, Goan YG, Lee H (2010) cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/ phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer. Clin Cancer Res 16: 5200-5210
42. Yoo BC, Jeon E, Hong SH, Shin YK, Chang HJ, Park JG (2004) Metabotropic glutamate receptor 4-mediated 5-fluorouracil resistance in a human colon cancer cell line. Clin Cancer Res 10: 4176-4184 (Pubitemid 38812498)